This standard specifies the criteria for determining the effectiveness of prevention and control of Kaschin-Beck Disease (KBD) in my country. This standard is applicable to the determination of the effectiveness of various prevention and control measures for Kaschin-Beck Disease by health administration and business departments at all levels across the country. GB 16397-1996 Determination of the effectiveness of prevention and control of Kaschin-Beck Disease GB16397-1996 Standard download decompression password: www.bzxz.net

GB16397-1996
The etiology of Kaschin-Beck Disease (KBD) has not yet been determined. So far, prevention and control measures have only been implemented based on three main etiology hypotheses. However, since there is no formal standard for determining the effectiveness of prevention and control measures at home and abroad, the effects of various measures cannot be scientifically compared. Researching effective prevention and control measures is a supplement and verification of etiology research, and is also a basic condition for measuring the effectiveness of prevention and control measures. To this end, based on the summary of previous prevention and control effect determination standards, combined with the research results of clinical, X-ray and disease area occurrence and development laws of Kaschin-Beck Disease in recent years, this standard has been formulated. This standard is a newly formulated industry standard for determining the effectiveness of Kaschin-Beck Disease prevention and control. This standard was proposed and coordinated by the Ministry of Health of the People's Republic of China. The drafting unit of this standard: Jilin Provincial Second Institute for the Prevention and Control of Endemic Diseases. The main drafters of this standard: Zhai Shusheng, Han Jingyuan, Zhai Junmin, Hu Ruiguang, Hou Xiang, Zhang Xueying, Lin Fuchun, Ge Xuguang, Liu Tiejun. This standard is interpreted by the China Endemic Disease Prevention and Control Research Center, the technical coordination unit entrusted by the Ministry of Health. 479Www.bzxZ.net
National Standard of the People's Republic of China
Judging criteria of preventive effect on Kashin-Beck disease
Judging criteria of preventive effect on Kashin-Beck disease This standard specifies the criteria for judging the preventive effect of Kashin-Beck disease (KBD) in my country. GB16397-1996
This standard applies to the judgment of the effectiveness of various preventive measures for Kashin-Beck disease by health administrative and business departments at all levels across the country. 2 Referenced standards
The provisions contained in the following standards constitute the provisions of this standard through reference in this standard. When this standard is published, the versions shown are valid. All standards will be revised, and the parties using this standard should explore the possibility of using the latest version of the following standards. GB16003—1995 Diagnostic criteria for Kashin-Beck disease 3 Conditions and period of observation population
3.1 Conditions of observation population Permanent residents who were born and raised locally and eat locally produced food. 3.2 Children aged 7 to 12 years old.
3.3 Health status Children with no KBD changes on right hand X-ray anteroposterior films. 3.4 Observation period once a year, for 5 consecutive years. 4 Criteria for judging the effectiveness of osteomalacia prevention and control
4.1 Significantly effective The following two conditions should be met after 5 years of implementing prevention and control measures in the ward. 4.1.1 No new clinical cases in the healthy population (see GB160034.1). 4.1.2 No new X-ray cases of trunk and bone ends in the healthy population (see GB160034.1). 4.2 Effective The following two conditions should be met after 5 years of implementing prevention and control measures in the ward. 4.2.1 The clinical new incidence rate of the healthy population is ≤2%. 4.2.2 The X-ray positive rate of the healthy population is ≤10% and/or the bone end positive rate is ≤3%. 4.3 During the invalid observation period, the morbidity rate of the healthy population in the early clinical stage and above I° (see GB160034.1) is >2% or the X-ray positive rate is >10% or the bone end positive rate is >3%.
Approved by the State Administration of Technical Supervision on May 23, 1996 480
Implemented on December 1, 1996
Tip: This standard content only shows part of the intercepted content of the complete standard. If you need the complete standard, please go to the top to download the complete standard document for free.